Gotowe bibliografie tematyczne / Proprotein convertase subtilisin/kexin type 9

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji

Gotowa bibliografia na temat „Proprotein convertase subtilisin/kexin type 9”

Autor: Grafiati
Data publikacji: 3 czerwca 2025
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Proprotein convertase subtilisin/kexin type 9”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Proprotein convertase subtilisin/kexin type 9"

1

Macchi, Chiara, Nicola Ferri, Chiara Favero, et al. "Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals." European Journal of Preventive Cardiology 26, no. 6 (2018): 578–88. http://dx.doi.org/10.1177/2047487318815320.

Pełny tekst źródła
Streszczenie:
Aims Exposure to airborne particulate matter has been consistently associated with early death and increased morbidity, particularly raising the risk of cardiovascular disease. Obesity, one of the leading cardiovascular disease risk factors, increases susceptibility to the adverse effects of particulate matter exposure. Proprotein convertase subtilisin/kexin type 9 has been related to a large number of cardiovascular risk factors, e.g. atherogenic lipoproteins, arterial stiffness and platelet activation. Thus, the present study was aimed at evaluating, in a series of obese individuals, the eff
Style APA, Harvard, Vancouver, ISO itp.
2

Stoekenbroek, Robert M., and John J. P. Kastelein. "Proprotein convertase subtilisin/kexin type 9." Current Opinion in Cardiology 33, no. 3 (2018): 269–75. http://dx.doi.org/10.1097/hco.0000000000000517.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Sahebkar, Amirhossein. "Proprotein Convertase Subtilisin/Kexin Type 9." Angiology 65, no. 3 (2013): 243. http://dx.doi.org/10.1177/0003319713512016.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Sinan, Umit Yasar. "Proprotein Convertase Subtilisin/Kexin Type 9." Angiology 65, no. 3 (2013): 244. http://dx.doi.org/10.1177/0003319713512558.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Bergeron, Nathalie, Binh An P. Phan, Yunchen Ding, Aleyna Fong, and Ronald M. Krauss. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition." Circulation 132, no. 17 (2015): 1648–66. http://dx.doi.org/10.1161/circulationaha.115.016080.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Farnier, Michel. "Proprotein convertase subtilisin kexin type 9 inhibitors." Current Opinion in Lipidology 27, no. 6 (2016): 597–604. http://dx.doi.org/10.1097/mol.0000000000000356.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Marais, David A., Dirk J. Blom, Francine Petrides, Yann Gouëffic, and Gilles Lambert. "Proprotein convertase subtilisin/kexin type 9 inhibition." Current Opinion in Lipidology 23, no. 6 (2012): 511–17. http://dx.doi.org/10.1097/mol.0b013e3283587563.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Zenti, Maria G., Anna Altomari, Maria G. Lupo, et al. "From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients." European Journal of Preventive Cardiology 25, no. 17 (2018): 1843–51. http://dx.doi.org/10.1177/2047487318792626.

Pełny tekst źródła
Streszczenie:
In this observational study, we compared the effect of lipoprotein apheresis and evolocumab or alirocumab on levels of lipoprotein cholesterol, triglycerides and inflammatory markers (C reactive protein and interleukin 6) in cardiovascular patients ( n = 9). Patients were monitored during the last year of lipoprotein apheresis followed by six months of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors. The biochemical parameters were determined pre- and post- every apheresis procedure for 12 months and then after one, three and six months of treatment with evolocumab (140
Style APA, Harvard, Vancouver, ISO itp.
9

Hess, Gregory P., Pradeep Natarajan, Kamil F. Faridi, Anna Fievitz, Linda Valsdottir, and Robert W. Yeh. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy." Circulation 136, no. 23 (2017): 2210–19. http://dx.doi.org/10.1161/circulationaha.117.028430.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Leong, Derek, and Peter E. Wu. "Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors." Canadian Medical Association Journal 191, no. 32 (2019): E894. http://dx.doi.org/10.1503/cmaj.190107.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Proprotein convertase subtilisin/kexin type 9"

1

Haas, Mary Elizabeth. "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Secondary Hyperlipidemias." Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:33493577.

Pełny tekst źródła
Streszczenie:
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has emerged over the past decade as an important regulator of plasma cholesterol and cardiovascular disease risk. PCSK9 promotes degradation of low density lipoprotein (LDL) receptors, thereby decreasing LDL clearance. Accordingly, patients with gain-of-function mutations in PCSK9 have increased LDL cholesterol and increased risk of cardiovascular disease. Conversely, PCSK9 inhibitors recently approved by the FDA are effective in reducing LDL cholesterol. While the contribution of PCSK9 to familial hypercholesterolemia is well-established,
Style APA, Harvard, Vancouver, ISO itp.
2

Balzarotti, G. "PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9)AND GLUCOSE METABOLISM: WHICH CONNECTION?" Doctoral thesis, Università degli Studi di Milano, 2018. http://hdl.handle.net/2434/543205.

Pełny tekst źródła
Streszczenie:
PCSK9 (proprotein convertase subtilisin/kexin type 9) and glucose metabolism: which connection? Background: PCSK9 (proprotein convertase subtilisin/kexin type 9), is a protein, mainly synthesized and secreted by the liver, which binds to specific target proteins and escorts them towards lysosomes for degradation. The best defined activity of PCSK9 is its ability to modulate the hepatic uptake of LDL cholesterol (LDL-C), by enhancing the intracellular degradation of the LDL receptor (LDLR). In humans, several mutations in PCSK9 gene were described, both “gain-of-function” mutations associate
Style APA, Harvard, Vancouver, ISO itp.
3

MARCHIANO', SILVIA. "CLINICAL AND EXPERIMENTAL EVIDENCES OF DIRECT VASCULAR EFFECT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9." Doctoral thesis, Università degli Studi di Milano, 2018. http://hdl.handle.net/2434/605175.

Pełny tekst źródła
Streszczenie:
Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), together with LDLR and APOB genes, had been identified as the third gene associated with Familial Hypercholesterolemia (FH). Secreted PCSK9 in fact, targets the hepatic LDL receptor (LDLR) for degradation thus preventing its recycling on the cell surface. The decreased expression of LDLR determines an increase in the circulating LDL particles, leading to increased cholesterol levels. Secreted PCSK9 is mainly derived from the liver, but it is also expressed in other tissues such as the brain, the kidney, the pancreas as well as the cells th
Style APA, Harvard, Vancouver, ISO itp.
4

Honorato, Aldrina Laura da Silva Costa. "Investigação de mutações no gene PCSK9 em famílias com diagnóstico clínico de Hipercolesterolemia Familiar." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/17/17138/tde-07122018-091850/.

Pełny tekst źródła
Streszczenie:
A hipercolesterolemia familiar (HF) é uma alteração de origem genética comum que pode se manifestar clinicamente desde o nascimento e provoca um aumento nos níveis plasmáticos de LDL-colesterol (LDL-c), xantomas e doença coronária prematura. Sua detecção e tratamento precoce reduzem a morbidade e mortalidade coronária. A identificação e rastreamento em cascata familiar usando níveis de LDL-c e detecção genética é a estratégia mais aconselhável e rentável para descoberta de novos casos. O tratamento crônico com estatinas reduz o risco cardiovascular da população em geral, contudo, estudos clíni
Style APA, Harvard, Vancouver, ISO itp.
5

CANCLINI, LAURA. "PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 PREFERENTIALLY ASSOCIATES WITH A SPECIFIC LDL SUBFRACTION: A DETAILED CHARACTERIZATION AND STUDY OF THE EFFECTS OF ANTI-PCSK9 MABS TREATMENT." Doctoral thesis, Università degli Studi di Milano, 2022. https://hdl.handle.net/2434/947250.

Pełny tekst źródła
Streszczenie:
BACKGROUND AND AIM: Proprotein Convertase Subtilysin/Kexin Type 9 is a key regulator of LDL-C levels. Nevertheless, its physiological modulation is not fully understood. It is unclear whether PCSK9 has biological effects other than degrading the LDLR; consensus is lacking also on how PCSK9 is transported in the bloodstream, and whether this influences PCSK9 function. There are several conflicting data about PCSK9’s possible association with different lipoprotein subtypes. The biological function of the lipoprotein-bound PCSK9, also, is still a matter of debate. Due to its role in modulating pl
Style APA, Harvard, Vancouver, ISO itp.
6

Ngqaneka, Thobile. "The impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)." University of Western Cape, 2020. http://hdl.handle.net/11394/7931.

Pełny tekst źródła
Streszczenie:
Magister Pharmaceuticae - MPharm<br>Cardiovascular diseases (CVDs) such as ischaemic heart diseases, heart failure and stroke remain a major cause of death globally. Various deep-rooted factors influence CVD development; these include but are not limited to elevated blood lipids, high blood pressure, obesity and diabetes. A considerable number of proteins are involved directly and indirectly in the transport, maintenance and elimination of plasma lipids, including high and low-density lipoprotein cholesterol (HDL-C and LDL-C). There are several mechanisms involved in the removal of LDL p
Style APA, Harvard, Vancouver, ISO itp.
7

Alghamdi, Rasha Hassen. "Development of Inhibitors of Human PCSK9 as Potential Regulators of LDL-Receptor and Cholesterol." Thesis, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/30492.

Pełny tekst źródła
Streszczenie:
Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) is the ninth member of the Ca+2-dependent mammalian proprotein convertase super family of serine endoproteases that is structurally related to the bacterial subtilisin and yeast kexin enzymes. It plays a critical role in the regulation of lipid metabolism and cholesterol homeostasis by binding to and degrading low-density lipoprotein-receptor (LDL-R) which is responsible for the clearance of circulatory LDL-cholesterol from the blood. Owing to this functional property, there is plenty of research interest in the development of functional inhibit
Style APA, Harvard, Vancouver, ISO itp.
8

Awan, Zuhier. "Proprotein convertase subtilisin/kexin type 9 in human disease." Thèse, 2011. http://hdl.handle.net/1866/5316.

Pełny tekst źródła
Streszczenie:
Les maladies cardiovasculaires (MCV) demeurent au tournant de ce siècle la principale cause de mortalité dans le monde. Parmi les facteurs de risque, l’hypercholestérolémie et l’obésité abdominale sont directement liées au développement précoce de l’athérosclérose. L’hypercholestérolémie familiale, communément associée à une déficience des récepteurs des lipoprotéines de basse densité (LDLR), est connue comme cause de maladie précoce d’athérosclérose et de calcification aortique chez l’humain. La subtilisine convertase proprotéine/kexine du type 9 (PCSK9), membre de la famille des proprotéines
Style APA, Harvard, Vancouver, ISO itp.
9

Leblond, François. "Régulation de la proprotéine convertase subtilisine / kexine type 9 (PCSK9) dans les cellules intestinales Caco-2/15." Thèse, 2008. http://hdl.handle.net/1866/2697.

Pełny tekst źródła
Streszczenie:
La proprotéine convertase subtilisine/kexine type 9 (PCSK9) favorise la dégradation post-transcriptionnelle du récepteur des lipoprotéines de faible densité (LDLr) dans les hépatocytes et augmente le LDL-cholestérol dans le plasma. Cependant, il n’est pas clair si la PCSK9 joue un rôle dans l’intestin. Dans cette étude, nous caractérisons les variations de la PCSK9 et du LDLr dans les cellules Caco-2/15 différentiées en fonction d’une variété d’effecteurs potentiels. Le cholestérol (100 µM) lié à l’albumine ou présenté en micelles a réduit de façon significative l’expression génique (30%, p<0,
Style APA, Harvard, Vancouver, ISO itp.
10

Durand, Loreleï. "PC7 : une protéase sécrétoire énigmatique ayant une fonction de sheddase et un ciblage cellulaire unique." Thèse, 2019. http://hdl.handle.net/1866/22519.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "Proprotein convertase subtilisin/kexin type 9"

1

Tuakli-Wosornu, Yetsa Adebodunde. Molecular and clinical chracterization of loss-of-function mutations in proprotein convertase subtilisin/kexin 9 (PCSK₉) and the genetic absence of PCSK₉. 2007.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "Proprotein convertase subtilisin/kexin type 9"

1

Guo, Shoudong, Xiao-dan Xia, Hong-mei Gu, and Da-wei Zhang. "Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism." In Advances in Experimental Medicine and Biology. Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6082-8_9.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Gallo, Antonio, Kévin Chemello, Romuald Techer, Ali Jaafar, and Gilles Lambert. "Role of Proprotein Convertase Subtilisin Kexin Type 9 in Lipoprotein(a) Metabolism." In Contemporary Cardiology. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24575-6_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Toth, Peter P. "Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition." In Contemporary Cardiology. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-56514-5_14.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Piotrowski, David W., and Emma L. McInturff. "Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors." In ACS Symposium Series. American Chemical Society, 2019. http://dx.doi.org/10.1021/bk-2019-1332.ch010.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Toth, Peter P., Manfredi Rizzo, and Maciej Banach. "Clinical Efficacy of Proprotein Convertase Synthase Kexin Type 9 Inhibition in Persons with Diabetes Mellitus." In Contemporary Diabetes. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-26681-2_27.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Marston, Nicholas A., and Marc S. Sabatine. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition." In Clinical Lipidology. Elsevier, 2024. http://dx.doi.org/10.1016/b978-0-323-88286-6.00020-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Limberakis, Chris, and David W. Piotrowski. "Recent Advances in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors." In 2021 Medicinal Chemistry Reviews. Medicinal Chemistry Division of the American Chemical Society, 2021. http://dx.doi.org/10.29200/acsmedchemrev-v56.ch4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Ramachandran, Sudarshan, Mithun Bhartia, and Carola S. König. "The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors." In Frontiers in Cardiovascular Drug Discovery: Volume 5. BENTHAM SCIENCE PUBLISHERS, 2020. http://dx.doi.org/10.2174/9789811413247120050003.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Thomas, Drew, Darma Marcelin, and Shone Almeida. "Changes in Atherosclerotic Plaque Composition with Anti-Lipid Therapy as Detected by Coronary Computed Tomography Angiography." In Management of Dyslipidemia. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96673.

Pełny tekst źródła
Streszczenie:
Lipid management remains the mainstay of cardiovascular disease prevention. Drugs that target cholesterol reduction, such as HMG-CoA reductase inhibitors (statins) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have shown significant mortality and morbidity benefit. Predominantly targeting low-density lipoprotein (LDL). These drugs have been indicated to reduce lipid composition and plaque proliferation. Total plaque burden and composition can now be assessed with noninvasive advanced cardiac imaging modalities. This chapter will address the components of atherosclerotic
Style APA, Harvard, Vancouver, ISO itp.
10

John Kumwenda, Mick. "Dyslipoprotemia." In Type 2 Diabetes - From Diagnosis to Effective Management [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.1002514.

Pełny tekst źródła
Streszczenie:
Dyslipoproteinaemia, also known as dyslipidaemia, occurs in more than 70% of people with diabetes and is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD) associated with obesity, hypertension, and poor glycaemic control. The prevalence of diabetes worldwide is increasing, and so is the death rate in people with diabetes. The causes of dyslipoproteinaemia are divided into primary (genetic) or secondary, which are diagnosed from history (diabetes, obesity, endocrine disorders, and chronic kidney disease). The pattern of dyslipoproteinaemia in diabetes typically consis
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Proprotein convertase subtilisin/kexin type 9"

1

Fang, C., T. Luo, and L. Lin. "AB1365 Proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with systemic lupus erythematosus/lupus nephritis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.1622.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Crossley, E., PK Hamilton, JA Silversides, DF McAuley, and CM O’Kane. "P108 The role of proprotein convertase subtilisin-kexin type 9 in the acute respiratory distress syndrome." In British Thoracic Society Winter Meeting 2024, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 27 to 29 November 2024, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2024. http://dx.doi.org/10.1136/thorax-2024-btsabstracts.269.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Aguilar, E., L. Dani, I. Moya Carmona, C. Estaun, and JM Fernández Ovies. "6ER-002 Assessement of efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (i-pcsk9) for hypercholesterolaemia with or without statins." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.495.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Remuzgo-Martínez, Sara, Fernanda Genre, Verónica Pulito-Cueto, et al. "FRI0006 PROTECTIVE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) RS2495477 POLYMORPHISM IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SUBCLINICAL ATHEROSCLEROSIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.2383.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Fang, C., L. Huang, T. Luo, X. Chen, and L. Lin. "AB0482 Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its correlation with C-reactive protein, but not atherogenic lipids in patients with systemic lupus erythematosus." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1487.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Ambel, H. Quiros, C. Donoso Rengifo, AA García Sacristán, et al. "4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.125.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Draz, Umar, Sana Yasin, Shafiq Hussain, et al. "Towards Investigating the Role of Proprotein Convertase Subtilisin/Kexin Family (PCSK/7/9) in Cancer by Using Bioinformatics Motif Detection Technique." In 2021 International Bhurban Conference on Applied Sciences and Technologies (IBCAST). IEEE, 2021. http://dx.doi.org/10.1109/ibcast51254.2021.9393179.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Aguilar-Valle, E., C. Estaun-Martinez, I. Moya-Carmona, M. Pedrosa-Ruiz, R. Mora-Santiago, and JM Fernández-Ovies. "CP-197 Protocol compliance in the treatment of hypercholesterolaemia with protein convertase SUBTILISIN-LIKE/KEXIN type 9 inhibitors (PCSK9 inhibitors)." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.195.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Proprotein convertase subtilisin/kexin type 9” dla poszczególnych typów źródeł:
Artykuły w czasopismach
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii